Expert Sandip Patel, MD, looks toward the promising future of lung cancer research, including targeted therapies, novel immunotherapy approaches, and the importance of biomarkers in guiding treatment decisions.
62-year-old woman presented to the ED with vague complaints of voice changes and cough.
Past Medical, Family, and Social History
Final Pathology: consistent with squamous cell carcinoma; metastatic stage IV
PD-L1 expression by IHC: 0%
NGS: No actionable mutations
Sandip P. Patel, MD: The future of lung cancer research is bright both in the domain of targeted therapies, using molecular testing to better understand the Achilles heels of cancer, and then adopting a targeted therapeutic approach, as well as the use of immunotherapy and novel immunotherapy targets such as TIGIT [T-cell immunoreceptor with immunoglobulin and ITIM (immunoreceptor tyrosine-based inhibitory motif) domain] or novel therapeutic modalities such as antibody-drug conjugates, which will help us increase our therapeutic armamentarium and determine the best particular option for a given patient. I think as we get more options, the importance of understanding the biomarker story for a given patient so we can best guide them on the appropriate treatment for the therapeutic journey remains key.
The ability for us to use a molecular map or an immunologic map in the form of next-generation sequencing, PD-L1 status, and hopefully other biomarkers to help guide the patient toward their best therapy will be key. We’re really looking forward to the ability for us to better understand which patients benefit from a particular immunotherapeutic strategy as we advance targeted therapy through the use of next-generation sequencing, in particular, liquid biopsy. Hopefully we’ll have similar multimodal tools to better understand the patient’s immune system so we can best adopt a particular immunotherapeutic strategy for the benefit of our patients.
Transcript is AI-generated and edited for readability.